| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/14/2010 | US20100009998 Compositions and Methods Employing Aminopterin |
| 01/14/2010 | US20100009997 Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug |
| 01/14/2010 | US20100009996 Methods and compositions for the treatment of metabolic disorders |
| 01/14/2010 | US20100009995 Maleate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-dihydro-5H-Pyrrolo[3,4-b]Pyrazine |
| 01/14/2010 | US20100009994 L-Malate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine |
| 01/14/2010 | US20100009993 Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents |
| 01/14/2010 | US20100009992 Ampk modulators |
| 01/14/2010 | US20100009991 Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
| 01/14/2010 | US20100009990 Imidazolyl pyrimidine inhibitor compounds |
| 01/14/2010 | US20100009989 Urea Glucokinase Activators |
| 01/14/2010 | US20100009988 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 01/14/2010 | US20100009987 Aminothiazole derivatives as inhibitors of mark |
| 01/14/2010 | US20100009986 Substituted heteroaryl derivatives |
| 01/14/2010 | US20100009985 THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS |
| 01/14/2010 | US20100009984 Aerosol formulations for the inhalation of beta-agonists |
| 01/14/2010 | US20100009983 5 ht receptor mediated neurogenesis |
| 01/14/2010 | US20100009982 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof |
| 01/14/2010 | US20100009981 Tetracycline Derivatives with Reduced Antibiotic Activity and Neuroprotective Benefits |
| 01/14/2010 | US20100009980 Novel 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| 01/14/2010 | US20100009979 Pharmaceuticals containing fluoroquinolones |
| 01/14/2010 | US20100009978 Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors |
| 01/14/2010 | US20100009977 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. |
| 01/14/2010 | US20100009976 Benzothiazin-3-one compound and intermediate therefor |
| 01/14/2010 | US20100009975 Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity |
| 01/14/2010 | US20100009974 Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them |
| 01/14/2010 | US20100009973 Integrase Inhibitors 3 |
| 01/14/2010 | US20100009972 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound |
| 01/14/2010 | US20100009971 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound |
| 01/14/2010 | US20100009970 Compositions and methods for treatment of viral diseases |
| 01/14/2010 | US20100009969 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands |
| 01/14/2010 | US20100009968 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
| 01/14/2010 | US20100009967 Solid dosage formulations of telcagepant potassium |
| 01/14/2010 | US20100009966 Substituted lactams as inhibitors of abeta protein production |
| 01/14/2010 | US20100009965 Cyclic malonamides as inhibitors of abeta protein production |
| 01/14/2010 | US20100009964 Compounds Which Modulate The CB2 Receptor |
| 01/14/2010 | US20100009963 Kinase antagonists |
| 01/14/2010 | US20100009962 Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| 01/14/2010 | US20100009961 Dipeptidyl peptidase-iv inhibitors |
| 01/14/2010 | US20100009960 Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 01/14/2010 | US20100009959 Pentacyclic Indole Derivatives as Antiviral Agents |
| 01/14/2010 | US20100009958 Quinazoline derivatives |
| 01/14/2010 | US20100009957 Novel inhibitors of beta-lactamase |
| 01/14/2010 | US20100009956 Novel substituted pyrimidines as cysteine protease inhibitors |
| 01/14/2010 | US20100009955 Pharmaceutical compositions of cefixime |
| 01/14/2010 | US20100009954 Beta-lactamase inhibitory compounds |
| 01/14/2010 | US20100009953 Cyclosporin derivatives for treating ocular and dermal diseases and conditions |
| 01/14/2010 | US20100009952 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 01/14/2010 | US20100009951 Ciclesonide containing sterile aqueous suspension |
| 01/14/2010 | US20100009950 Substituted ethanolamines |
| 01/14/2010 | US20100009949 Novel method |
| 01/14/2010 | US20100009948 Combined calcium, magnesium and vitamin D supplements |
| 01/14/2010 | US20100009947 2-Methylene-19,26-Dinor-(20S,22E,25R)-Vitamin D Analogs |
| 01/14/2010 | US20100009946 2-Methylene-19,26-Dinor-(20R,22E,25R)-Vitamin D Analogs |
| 01/14/2010 | US20100009945 3,2-dihydrofuran-1 alpha ,25-dihydroxy-19-nor-vitamin D3; prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases; osteoporosis |
| 01/14/2010 | US20100009944 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring |
| 01/14/2010 | US20100009943 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs |
| 01/14/2010 | US20100009942 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs |
| 01/14/2010 | US20100009941 2-Methylene-20(21)-Dehydro-19-Nor-Vitamin D Analogs |
| 01/14/2010 | US20100009940 2-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs |
| 01/14/2010 | US20100009939 Concurrent drugs |
| 01/14/2010 | US20100009938 Method to identify and treat subjects resistant to acetyl salicylic acid |
| 01/14/2010 | US20100009936 Chemical compounds |
| 01/14/2010 | US20100009935 Resistance-repellent retroviral protease inhibitors |
| 01/14/2010 | US20100009934 Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| 01/14/2010 | US20100009932 Liquid Satiety Enhancing Composition |
| 01/14/2010 | US20100009930 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents |
| 01/14/2010 | US20100009929 Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| 01/14/2010 | US20100009928 Compositions including triciribine and taxanes and methods of use thereof |
| 01/14/2010 | US20100009927 Anti-Inflammatory and Anti-Allergy Extracts from Nettle |
| 01/14/2010 | US20100009926 Ph-sensitive polymeric micelles for drug delivery |
| 01/14/2010 | US20100009925 18-membered macrocycles and analogs thereof |
| 01/14/2010 | US20100009924 Compositions and methods for improving cardiovascular function |
| 01/14/2010 | US20100009921 Pharmaceutical compositions and methods for peptide treatment |
| 01/14/2010 | US20100009920 Ttk as tumor marker and therapeutic target for lung cancer |
| 01/14/2010 | US20100009909 Peptides binding the phosphatase 2a protein |
| 01/14/2010 | US20100009906 Anticancer Treatments |
| 01/14/2010 | US20100009905 Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer |
| 01/14/2010 | US20100009900 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy} beta -D-glucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, cataracts |
| 01/14/2010 | US20100009896 Capture agents and related compositions, methods and systems |
| 01/14/2010 | US20100009895 Method for selective localization of active agents at and in mitochondria and corresponding active agents |
| 01/14/2010 | US20100009017 Anticancer Methods Using Extracts of Anemarrhena asphodeloides Bunge |
| 01/14/2010 | US20100009015 Use of chromium histidinate for treatment of cardiometabolic disorders |
| 01/14/2010 | US20100009013 Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression |
| 01/14/2010 | US20100009005 Novel acetysalicylic acid formulations |
| 01/14/2010 | US20100009003 Pharmaceutical preparation to be dispersed before administration |
| 01/14/2010 | US20100008998 Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
| 01/14/2010 | US20100008995 Processes for preparing pharmaceutical compositions |
| 01/14/2010 | US20100008993 Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs |
| 01/14/2010 | US20100008991 Transdermal estrogen device and delivery |
| 01/14/2010 | US20100008990 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 01/14/2010 | US20100008988 Tablet compositions of amine polymers |
| 01/14/2010 | US20100008987 Modified Release Pharmaceutical Composition of Bupropion Hydrochloride |
| 01/14/2010 | US20100008986 Pharmaceutical compositions comprising sumatriptan and naproxen |
| 01/14/2010 | US20100008985 Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| 01/14/2010 | US20100008984 Solid dispersions comprising tacrolimus |
| 01/14/2010 | US20100008983 Rasagiline soft gelatin capsules |
| 01/14/2010 | US20100008982 Non-covalent complexes of bioactive agents with starch for oral delivery |
| 01/14/2010 | US20100008981 Methods and sequences to suppress primate huntington gene expression |
| 01/14/2010 | US20100008979 Delivery of therapeutic agents to the bone |
| 01/14/2010 | US20100008978 Nanoparticles effective for internalization into cells |